Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Richard Follows"'
Autor:
William V. Williams, Lee Evitt, Richard Follows, Robyn von Maltzahn, Michael Celone, Shibing Yang, Huda Shalhoub
Publikováno v:
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..
Background: Mepolizumab (Nucala®) is licensed for severe eosinophilic asthma (SEA). Autoinjector (AI) and prefilled syringe (PFS) have been developed to enable in-clinic and at-home self-administration which may improve patient treatment experience.
Autor:
William V. Williams, Jane H Bentley, Richard Follows, H. Shalhoub, R von Maltzahn, A. Gruber, Lee Evitt, M. Celone
Publikováno v:
Revue des Maladies Respiratoires Actualités. 12:174-175
Introduction Le mepolizumab est autorise depuis 2015 aux Etats-Unis pour le traitement de l’asthme severe a eosinophiles (ASE). Il est actuellement administre en milieu hospitalier par des professionnels de sante (PDS) sous forme de poudre lyophili
Publikováno v:
Airway pharmacology and treatment.
Introduction: Mepolizumab (Nucala®) is licensed for severe eosinophilic asthma (SEA). A prefilled autoinjector (AI) has been developed to enable in-clinic and at-home, self-administration which may improve the patient treatment experience (PTE). Obj
Autor:
Richard Follows, H. Shalhoub, R von Maltzahn, William V. Williams, Lee Evitt, M. Celone, Jane H Bentley
Publikováno v:
A32. ASTHMA: CLINICAL STUDIES II.
Autor:
Ian D. Pavord, Kenneth R. Chapman, I. Pouliquen, David I. Bernstein, Richard Follows, J.H. Bentley, Eric S. Bradford
Publikováno v:
A32. ASTHMA: CLINICAL STUDIES II.
Autor:
Richard Follows, Jane H Bentley, David I. Bernstein, Eric S. Bradford, Isabelle Pouliquen, Elisabeth H. Bel, Leif Bjermer
Publikováno v:
Journal of asthma, 57(7), 755-764. Informa Healthcare
Objective: A liquid mepolizumab formulation in a single-use prefilled syringe (PFS) is under development. We evaluated the usability of mepolizumab self-injected via PFS by patients with severe eosinophilic asthma (SEA), or their caregivers, in clini
Autor:
Dawn Midwinter, Neil Barnes, Steffen E. Petersen, Ian S Stone, Leonette John, Redha Boubertakh, Richard Follows, Wai-Yee James
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 193:717-726
Patients with chronic obstructive pulmonary disease develop increased cardiovascular morbidity with structural alterations.To investigate through a double-blind, placebo-controlled, crossover study the effect of lung deflation on cardiovascular struc
Publikováno v:
Current Medical Research and Opinion. 29:1663-1674
To investigate the clinical benefits of ‘add-on’ therapy with GSK2190915 in combination with the inhaled corticosteroid (ICS) fluticasone propionate (FP) and the ICS/long-acting beta 2 agonist (LABA) combination FP/salmeterol in asthmatic subject
Autor:
Ian D. Pavord, Richard Follows, Eric S. Bradford, Charlene M. Prazma, Oliver N. Keene, Steven W. Yancey, Necdet B Gunsoy, Frank C. Albers
Publikováno v:
Journal of Allergy and Clinical Immunology. 139:AB9
Autor:
Brett Haumann, Eugene R. Bleecker, Jessica Lim, Sally Stone, Jan Lötvall, Richard Follows, Eric D. Bateman, William W. Busse, Loretta Jacques, Ashley Woodcock
Publikováno v:
The European respiratory journal. 40(3)
Current guidelines recommend adding a long-acting inhaled β(2)-agonist (LABA) to inhaled corticosteroids (ICS) in patients with uncontrolled asthma. This study evaluated the novel, once-daily LABA vilanterol trifenatate (VI) in asthma patients who r